Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;16(5):552-557.
doi: 10.1159/000519562. Epub 2021 Sep 29.

Expert Discussion: Predictive Markers

Angelo Paradiso  1 , Giovanni Codacci-Pisanelli  2 , Elisabetta Munzone  3 , Hope S Rugo  4 , Pierre Etienne Heudel  5
Affiliations

Expert Discussion: Predictive Markers

Angelo Paradiso et al. Breast Care (Basel). 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Angelo Paradiso: no conflict of interest to disclose. Giovanni Codacci-Pisanelli: no conflict of interest to disclose. Elisabetta Munzone: consulting or advisory role for Genomic Health, Pierre Fabre, and Eisai. Hope S. Rugo: research support for clinical trials through the University of California to Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Astra Zeneca, OBI and Gilead, Ayala; honoraria: Puma, Mylan, Samsung. Pierre Etienne Heudel: grants, personal fees, and nonfinancial support from Pfizer, grants and nonfinancial support from Novartis, grants and nonfinancial support from Roche, grants, personal fees, and nonfinancial support from Astra Zeneca, personal fees and nonfinancial support from Mylan, grants, personal fees, and nonfinancial support from Pierre Fabre, personal fees and nonfinancial support from Amgen and personal fees and nonfinancial support from Seagen.

References

    1. Tutt AN, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. OlympiA Clinical Trial Steering Committee and Investigators Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun;384((25)):2394–405. - PMC - PubMed
    1. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. ESMO Guidelines Committee Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016 Sep;27(suppl 5):v103–10. - PubMed
    1. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. IMpassion130 Trial Investigators Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov;379((22)):2108–21. - PubMed
    1. Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020 May;31((5)):569–81. - PubMed
    1. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. FDA U.S. Food and Drug. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atez...Accessed 16 May 2020. - PubMed